Related Experiment Video
Updated: May 29, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Renal sympathetic denervation in hypertension.
Michael Doumas1, Charles Faselis, Vasilios Papademetriou
1Veterans Affairs Medical Center - George Washington University, Washington, DC 20422, USA. michalisdoumas@yahoo.co.uk
Current Opinion in Nephrology and Hypertension
|September 3, 2011
Summary
Renal sympathetic denervation effectively lowers blood pressure in patients with resistant hypertension. This catheter-based procedure is safe and durable, offering a promising interventional option for managing difficult-to-treat hypertension.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Nephrology
Background:
- Resistant hypertension is a significant clinical challenge despite numerous antihypertensive medications.
- Interventional management, particularly renal sympathetic denervation, is a rapidly advancing area in hypertension research.
Purpose of the Study:
- To review the pathophysiologic basis and mechanisms of blood pressure reduction following renal sympathetic denervation.
- To analyze recent findings on renal sympathetic denervation for resistant hypertension.
- To propose future research directions for this interventional approach.
Main Methods:
- Review of existing literature on renal sympathetic denervation.
- Analysis of proof-of-concept and randomized controlled studies.
- Evaluation of safety and efficacy data from clinical trials.
Main Results:
- Catheter-based renal sympathetic denervation demonstrated significant blood pressure reduction (approx. 30/15 mmHg) at 6 months in resistant hypertension patients.
- The procedure was associated with no serious complications and showed 2-year durability of blood pressure lowering.
- Controlled, randomized studies confirmed the efficacy and safety of ablation-induced renal denervation.
Conclusions:
- Ablation-induced renal denervation is a feasible, effective, and well-tolerated interventional treatment for resistant hypertension.
- This approach holds potential for other conditions involving sympathetic overactivity, warranting further rigorous investigation.
- Future research should focus on identifying the full potential, limitations, indications, and contraindications of renal denervation.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:18Disorders of the Autonomic Nervous System
The autonomic nervous system (ANS) is an intricate network of nerves that controls functions such as the regulation of heart rate, digestion, and blood pressure regulation. When this system malfunctions, it can lead to various disorders that affect multiple bodily functions. One common feature of many autonomic disorders is the involvement of smooth blood vessels, which play a crucial role in regulating blood flow throughout the body.
Raynaud's disease, also known as Raynaud's phenomenon, is a...
Raynaud's disease, also known as Raynaud's phenomenon, is a...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:18Neural Regulation of Blood Pressure
The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...